2M2B

# Research Output: 2M2B (2-Methylbutan-2-ol)

**PSX ID:** PSX-0041 | **Slug:** 2m2b | **Type:** Compound | **Class:** Depressant alcohol

---

## Chemical Identity

**Verified via PubChem CID 6405 [Ref 14/24]:**

| Property | Value |
|---|---|
| IUPAC name | 2-methylbutan-2-ol |
| Common names | tert-Amyl alcohol (TAA), amylene hydrate, 2M2B |
| CAS number | 75-85-4 |
| PubChem CID | 6405 |
| Molecular formula | C₅H₁₂O |
| Molecular weight | 88.15 g/mol |
| InChIKey | MSXVEPNJUHWQHW-UHFFFAOYSA-N |
| SMILES | CCC(C)(C)O |

**Note:** The seed data left SMILES, molecular formula, molecular weight, and PubChem CID blank. All four are now confirmed from PubChem (CID 6405). The SMILES CCC(C)(C)O represents the tertiary alcohol structure correctly (ethyl group + two methyl groups on the carbinol carbon).

**Physical properties (web-retrieved, from HandWiki [Ref 24]):**
- Boiling point: 101–103 °C
- Melting point: −9 °C
- Density: 0.805 g/cm³ at 25 °C
- Water solubility: 120 g/L
- Vapor pressure: 1.6 kPa at 20 °C
- Flash point: 19 °C (flammable liquid)
- Appearance: Colorless liquid with an unpleasant odor and burning flavor

**Production:** Primarily made by the acid-catalyzed hydration of 2-methyl-2-butene. Alternative synthesis via Favorskii reaction using acetone and acetylene, followed by hydrogenation [Ref 24].

**Natural occurrence:** Trace amounts found as fermentation byproducts in alcoholic beverages; also detected in fried bacon, cassava, rooibos tea, and rabbit milk (where it appears to function as a pheromone inducing suckling behavior in newborns) [Ref 24].

---

## Pharmacology

### Mechanism of Action

2M2B is a tertiary alcohol that acts as a positive allosteric modulator (PAM) of GABA-A receptors in the same manner as ethanol [Refs 1, 14]. It also inhibits NMDA glutamate receptors. No specific binding affinity data (Ki/EC50) for 2M2B at GABA-A or NMDA receptors have been published in peer-reviewed literature. The mechanistic characterization below is based on class-level evidence from ethanol and other aliphatic alcohols.

**GABA-A receptor modulation:**
2M2B potentiates GABA-mediated chloride ion influx at GABA-A receptors. This is the same mechanism shared by ethanol, benzodiazepines, barbiturates, and neurosteroids, though each binds at distinct allosteric sites. Chronic exposure leads to compensatory downregulation of δ-subunit–containing GABA-A receptors (rapid tolerance) and α1-subunit–containing receptors (cross-tolerance to benzodiazepines, anesthetics, and neurosteroids). Chronic intermittent exposure produces persistent subunit composition changes lasting months in rodents (Olsen & Liang 2017 [Ref 10]).

**NMDA receptor antagonism:**
Lovinger et al. (1989 [Ref 11]) demonstrated that alcohols inhibit NMDA-activated ion current in hippocampal neurons in a concentration-dependent manner, and that the potency for NMDA inhibition is **linearly related to intoxicating potency** across a series of alcohols. This strongly implies that 2M2B — which is approximately 20× more intoxicating than ethanol by weight — exerts proportionally greater NMDA receptor inhibition. The inhibition is non-competitive and voltage-independent; ethanol does not act as a pore blocker or compete with glutamate or glycine (Peoples et al. 1997 [Ref 13]).

**⚠️ FLAG:** No substance-specific binding affinity data (Ki, EC50, IC50) for 2M2B at any receptor target exist in the peer-reviewed literature. All pharmacological mechanisms are inferred from structural class (tertiary alcohol) and published data on ethanol and related aliphatic alcohols.

### Pharmacokinetics

**Metabolism (Amberg et al. 1999 [Ref 5]; Dekant et al. 2001 [Ref 6]; Amberg et al. 2000 [Ref 7]):**

2M2B is **not metabolized by alcohol dehydrogenase (ADH)**. As a tertiary alcohol, it lacks an oxidizable hydrogen at the carbinol carbon, preventing the ADH-mediated conversion to an aldehyde that causes the acetaldehyde toxicity and hangover associated with ethanol. Instead, 2M2B undergoes **cytochrome P450–dependent oxidation**, producing:
- 2-Methyl-2,3-butanediol (free and glucuronide-conjugated) — major metabolite
- 2-Hydroxy-2-methylbutyric acid — significant urinary metabolite
- 3-Hydroxy-3-methylbutyric acid — significant urinary metabolite

These metabolites are non-toxic in comparison to acetaldehyde, which accounts for the lack of hangover reported by users.

**Human elimination kinetics:**
In studies where human volunteers were exposed to TAME (tert-amyl methyl ether, which is metabolized to 2M2B/TAA), urinary metabolite elimination half-lives ranged from **6 to 40 hours** in humans — markedly slower than in rats (under 6 hours) (Amberg et al. 2000 [Ref 7]; Dekant et al. 2001 [Ref 6]). This extended metabolite clearance is consistent with the prolonged clinical intoxication duration documented in case reports.

**Detection:**
2M2B is **not detected by standard immunoassay urine toxicology screens** used in emergency and occupational settings. Gas chromatography–mass spectrometry (GC-MS) can confirm use and detect TAA in blood and urine samples. The glucuronide metabolite of TAA may cause false-positive results on immunological ethyl glucuronide (EtG) screening, as discussed by Arndt et al. (2017 [Ref 3]).

**Bioavailability/Absorption:**
After oral ingestion, 2M2B is rapidly absorbed from the gastrointestinal tract. Hepatic first-pass metabolism is not observed for its structural analog TAME, and a significant proportion of dose is transferred directly into blood (Dekant et al. 2001 [Ref 6]). No direct human oral bioavailability study for 2M2B exists.

**CYP Enzyme involvement:**
CYP2E1 and CYP2B1 are implicated in metabolism. Studies on the structurally related compound TAME showed 2-fold CYP2E1 induction and up to 260-fold CYP2B1 induction in rats (Elovaara et al. 2007 [Ref 9]). By extension, CYP2E1 and CYP2B1 are the primary enzymes responsible for 2M2B oxidation. CYP2E1 substrates (e.g., disulfiram, some industrial solvents) may inhibit 2M2B clearance.

---

## History

### Pre-clinical and pharmacological discovery
2-Methylbutan-2-ol (tert-amyl alcohol) has been known as a chemical since the mid-19th century. Its pharmacological properties were first formally described in medical literature by **D.W. Yandell** in an 1888 publication titled "Amylene hydrate, a new hypnotic" in *The American Practitioner and News* [Ref 23]. Under the name **amylene hydrate**, it was used as an anesthetic and sedative-hypnotic agent from approximately **1880 to 1950** [Ref 14, 24]. It was rarely used clinically because more efficient and better-characterized agents (chloroform, diethyl ether, chloral hydrate) were available.

### Avertin formulation
In the **1930s**, tert-amyl alcohol was used primarily as a **solvent for tribromoethanol (TBE)** in the anesthetic formulation known as **Avertin** (brand name by Winthrop Laboratories). This mixture was administered rectally for surgical anesthesia and continued in use for laboratory animals (rodents) through the mid-20th century [Refs 14, 24].

### Re-emergence as recreational substance
The substance re-emerged on **internet drug forums** in the late 2000s–early 2010s. Abuse was initially documented predominantly in **Eastern Europe** (Poland, other countries), where it was promoted among alcohol- and drug-dependent individuals seeking a cheap, more potent, hangover-free, and undetectable alternative to ethanol (Rusiecka et al. 2016 [Ref 2]; Anand et al. 2014 [Ref 4]).

The compound is sold under names such as "Vodka" on Eastern European markets (Rusiecka et al. 2016 [Ref 2]) and via online "legal high" vendors, typically in 5 or 10 mL doses. The designation "2M2B" circulates on internet platforms including Reddit, Erowid, Drugs-Forum, and English-language harm reduction communities (Arndt et al. 2017 [Ref 3]; Syed & Leo 2022 [Ref 1]).

**Key published timeline:**
- **1888** — First described as "amylene hydrate, a new hypnotic" by Yandell [Ref 23]
- **~1930s** — Used as Avertin solvent [Ref 24]
- **2014** — First case report of acute intoxication published (Anand et al., FSI) [Ref 4]
- **2016** — Cytotoxicity comparison study published (Rusiecka et al., Toxicology in Vitro) [Ref 2]
- **2017** — Forensic context paper on novel psychoactive alcohols (Arndt et al., FSI) [Ref 3]
- **2022** — Two case reports published: Syed & Leo (PCCNSD) [Ref 1]; e-psychonauts case study [Ref 17]
- **2024** — ICU intoxication case report (HCA Healthcare) [Ref 18]

---

## Subjective Effects

### Published clinical descriptions
Syed & Leo (2022 [Ref 1]) describe a case where 20–25 mL of 2M2B produced: **slurred speech, gross motor incoordination, memory and concentration impairments, and delirium** lasting approximately 3 days. They note that smaller doses (7.5 mL) are advocated by users to produce "warm feelings, relaxation, talkativeness, and mildly euphoric and anxiolytic effects" equivalent to the effects of approximately 150 mL of standard liquor.

The e-psychonauts case study (ScienceDirect 2022 [Ref 17]) describes a presentation with growing use on online forums where effects are praised as "cheap alternative to ethanol with only little caution to related health risks." Reported symptoms in the case included urinary retention, low mood, reduced cognitive functioning, ataxia, and respiratory depression in the severe presentation.

### User-report characterization
A user experience report from Erowid (2012 [Ref 19]) documents: total dose ~10.4 g over 2 hours; subjective euphoria described as "more intense than ethanol"; relaxation and serenity; effects lasted approximately 8–10 hours; minimal hangover the following day; notable unpleasant taste (described as peppermint-like with chemical notes); mild motor incoordination at higher doses.

Community characterization (PsychonautWiki [Ref 16]) describes 2M2B as producing effects "comparatively closer to alcohol than GHB in terms of its subjective effects" and "considerably more sedating than alcohol but less sedating than GHB."

### Effect domains documented
The following effects are consistent with published case descriptions and user reports (all user-report quality unless specified; no controlled dosing studies exist):
- **Sedation** (clinical documentation, all case reports)
- **Motor control impairment / ataxia** (clinical: Syed & Leo 2022; user reports)
- **Cognitive impairment / memory suppression** (clinical: Syed & Leo 2022)
- **Disinhibition, euphoria, anxiety suppression** (user reports; pharmacological class inference)
- **Respiratory depression** (clinical: Anand 2014, HCA Healthcare 2024 intubation case)
- **Delirium** at high doses (clinical: Syed & Leo 2022)
- **Muscle relaxation** (pharmacological class inference from GABA-A PAM)

### Duration
Seed data: total 8–14 hours. Clinical reports (Syed & Leo 2022 [Ref 1]) suggest intoxication can persist **12–24 hours** after a significant dose, with delirium lasting up to 3 days. The metabolite elimination half-life data (6–40 hours in humans [Ref 7]) supports an extended effect window.

**⚠️ FLAG for editorial review:** The seed data's total duration of 8–14 hours is likely accurate for typical recreational doses. However, clinical literature suggests higher doses can produce substantially longer intoxication (12–24 hours or more). The generation agent should note this dose-dependency clearly.

---

## Safety & Toxicity

### Acute toxicity
**Human fatality:** The lowest recorded fatal dose in humans reported in community sources is **30 mL** [Ref 24]. This figure is unverified by a peer-reviewed primary source and should be treated with caution. No LD₅₀ data for humans exist in published literature.

**Animal toxicity (web-retrieved [Ref 24]):** Rat oral LD₅₀ approximately **1 g/kg** body weight. This figure requires verification against the primary ORNL toxicity assessment (hhpprtv.ornl.gov) which could not be retrieved (PDF binary encoding issue). **⚠️ FLAG: Rat LD₅₀ sourced from HandWiki only; not independently verified via primary source.**

**In vitro:** Rusiecka et al. (2016 [Ref 2]) demonstrated that 2M2B cytotoxicity in HEK293 cells (MTT assay) is comparable to ethanol and significantly lower than 3-methyl-1-butanol. Li et al. (2018 [Ref 8]) showed 2M2B induces cell cycle arrest and autophagy in retinoblastoma cells via PI3K/Akt pathway and is cytotoxic to normal cells at higher concentrations.

### Clinical presentations and case data
**Case 1 — Anand et al. (2014 [Ref 4]):** 28-year-old male found in deep coma with acute respiratory failure due to recreational TAA intoxication. Blood TAA level at admission: 83 μg/mL determined by GC-MS. Patient required intensive support. Documents growing European abuse trend in context of addiction self-medication and detection evasion.

**Case 2 — Syed & Leo (2022 [Ref 1]):** 25-year-old male presented to ED with altered mental status after consuming 20–25 mL of 2M2B. Vitals: BP 154/89 mmHg (hypertensive), HR 130 bpm (tachycardic), RR 26 breaths/min (tachypneic). Labs: anion gap 26 mEq/L (elevated), serum osmolality 311 mOsm/kg (elevated), β-hydroxybutyrate 4 mmol/L (elevated), AST 62 IU/L (mildly elevated). Standard urine toxicology screen was negative. Symptoms of intoxication gradually resolved over 3 days; patient discharged on day 4.

**Case 3 — e-psychonauts (ScienceDirect 2022 [Ref 17]):** 26-year-old male, first case report on withdrawal treatment of acute 2M2B intoxication and addiction. Details on management approach documented but full article not accessible.

**Case 4 — HCA Healthcare (2024 [Ref 18]):** 41-year-old female found altered on scene by EMS. Had ingested 2M2B prior to EMS arrival. Required intubation in the field; admitted to ICU. Diagnosis: 2M2B intoxication.

### Toxicological interpretation
The osmolar gap elevation in Case 2 (osmolality 311 vs. normal ~285–295) is consistent with an unidentified osmotically active compound in blood — a pattern seen with all toxic alcohols. The elevated anion gap and β-hydroxybutyrate suggest either secondary ketogenesis or a component of toxic alcohol metabolism. Elevated AST suggests mild hepatic stress.

### Respiratory risk
Acute respiratory failure requiring intubation is documented (Anand 2014 [Ref 4]; HCA Healthcare 2024 [Ref 18]). Respiratory depression is a class effect of GABA-A positive allosteric modulators and is dose-dependent. This represents the primary life-threatening toxicity of 2M2B.

---

## Harm Reduction

### Detection evasion concerns
2M2B is not detected on standard immunoassay urine or breath alcohol screens [Refs 1, 4, 17]. This creates diagnostic challenges in emergency settings and enables users to circumvent mandatory drug testing in workplace, legal, and treatment contexts. GC-MS analysis of blood or urine is required for detection [Ref 4].

### Interaction risks
No dedicated 2M2B drug interaction studies exist. By pharmacological class, the following interactions are expected (all by class inference):
- **CNS depressants (opioids, benzodiazepines, barbiturates, GHB, alcohol):** Synergistic CNS and respiratory depression; potentially fatal. Cross-tolerance with GABA-A PAMs means that individuals with alcohol or benzodiazepine tolerance may require higher doses for effect while maintaining respiratory risk [Refs 10, 21].
- **CYP2E1 inhibitors (disulfiram, some industrial chemicals):** May impair clearance of 2M2B, prolonging and intensifying intoxication.
- **Other GABA-A modulators:** Additive effects at GABA-A receptors.

**⚠️ Safety-critical flag:** All interaction data are class-level inferences from ethanol pharmacology. No published 2M2B-specific interaction studies exist.

### Identification and testing
2M2B is available commercially as an industrial solvent and reagent. Users sourcing from chemical suppliers receive the compound without pharmaceutical-grade purity or dosing information. Concentration may vary. No validated consumer drug test exists for 2M2B.

### Emergency management
There is no specific antidote. Based on case reports, management is supportive: airway management (intubation may be required), monitoring of respiratory and cardiovascular status, correction of metabolic derangements. Benzodiazepines are standard treatment for seizures and agitation in GABAergic withdrawal. The elevated osmolar gap in case reports suggests that standard alcohol poisoning protocols (monitoring for respiratory depression, supportive care) are appropriate.

---

## Tolerance & Dependence

### Tolerance
The seed data states: "develops with prolonged and repeated use; half-life 5 days; full reset 1.5 weeks; cross-tolerances: GABA, depressants."

The tolerance half-life of 5 days and full reset of 1.5 weeks cannot be verified against any published primary source for 2M2B specifically. These values appear to be community-consensus estimates. **⚠️ FLAG: Tolerance timeline values are unverified community consensus; no peer-reviewed pharmacokinetic tolerance data for 2M2B exists.**

Cross-tolerance with other GABAergic drugs (benzodiazepines, barbiturates, neurosteroids, other alcohols) is supported by extensive class-level evidence from ethanol research (Olsen & Liang 2017 [Ref 10]; Allan et al. 1992, cross-tolerance between lorazepam, ethanol, and phenobarbital on GABA-Cl- flux).

### Physical dependence
Physical dependence develops with repeated use, consistent with all GABA-A PAMs. Withdrawal from chronic 2M2B use is expected to produce a syndrome resembling alcohol/benzodiazepine withdrawal: tremor, anxiety, insomnia, sweating, seizures, and potentially delirium tremens [Refs 1, 17, 20, 21]. The seed data characterizes dependence as moderate physical, moderate psychological, with "moderately addictive with high potential for abuse."

The e-psychonauts case study (2022 [Ref 17]) is described as "the first case report on the withdrawal treatment of a 26-year-old male patient with acute intoxication and addiction to 2m2b," confirming that clinical dependence requiring managed withdrawal has been documented.

**⚠️ FLAG:** No quantitative dependence liability data (e.g., DSM-defined AUD prevalence in 2M2B users, reinforcing dose-response, self-administration studies) have been published for 2M2B. Dependence liability characterization is by class inference from ethanol and other GABA-A PAMs.

---

## Interactions

| Combination | Risk | Mechanism | Source |
|---|---|---|---|
| Opioids | **Dangerous** | Synergistic CNS and respiratory depression | Class inference [Ref 10] |
| Benzodiazepines | **Dangerous** | Additive GABA-A modulation | Class inference [Refs 10, 21] |
| Barbiturates | **Dangerous** | Additive GABA-A modulation | Class inference |
| Alcohol (ethanol) | **Dangerous** | Additive GABA-A PAM + NMDA antagonism | Syed & Leo 2022 [Ref 1] |
| GHB/GBL | **Dangerous** | Additive CNS/respiratory depression | Class inference |
| Gabapentinoids | **Caution** | Enhanced CNS depression | Class inference |
| CYP2E1 inhibitors | **Caution** | Impaired clearance → prolonged intoxication | Metabolic inference [Refs 5–7] |

**⚠️ FLAG:** All interaction classifications are derived from pharmacological class inference from ethanol data. No published 2M2B-specific drug interaction studies exist.

---

## Legal Status

| Jurisdiction | Status | Details |
|---|---|---|
| United Kingdom | **Illegal** | Covered by Psychoactive Substances Act 2016 (effective May 26, 2016); production, supply, and import prohibited |
| Germany | **Prescription** | Listed as "Amylenhydrat" under Anlage 1 AMVV (Arzneimittel-und Wirkstoffherstellungsverordnung); requires prescription |
| United States | **Unscheduled** | Not listed in DEA Orange Book; available as an industrial solvent/reagent; not a federally scheduled controlled substance |
| Australia | **Unclear** | Community claims regarding analogue act applicability are disputed; no confirmed scheduling found |
| Canada | **Unclear** | No specific scheduling identified in search results |
| European Union | **Unscheduled** (generally) | Listed on ECHA substances register as an industrial chemical; REACH regulations apply to industrial use; no explicit NPS scheduling found |

**Source note:** UK and German data are web-retrieved [Refs 16, web searches]; US status from DEA database review; Australia/Canada unresolved. **⚠️ FLAG: Legal status requires editorial verification, particularly for Australia, Canada, and EU member states.**

---

## Clinical Trials

No clinical trials for 2M2B (2-methylbutan-2-ol, tert-amyl alcohol) were identified in a search of ClinicalTrials.gov. No registered studies exist examining 2M2B for any therapeutic indication.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to analyze.

---

## Gaps & Flags

### Critical safety-critical gaps
1. **⚠️ Rat LD₅₀ (1 g/kg) and human fatal dose (30 mL minimum)** — Both values are sourced from tertiary web sources (HandWiki). Neither was confirmed against a primary research publication or regulatory toxicity assessment. The ORNL provisional peer-reviewed toxicity assessment document (PDF) could not be decoded. Generation agent must not present these as peer-reviewed values.

2. **⚠️ All drug interaction classifications** are derived from ethanol pharmacology by class inference. No 2M2B-specific interaction data exist.

3. **⚠️ Tolerance timeline (5 days half-life; 1.5-week reset)** — No peer-reviewed source found. Community consensus only.

4. **⚠️ Binding affinity data (Ki, EC50 at GABA-A or NMDA)** — No published data for 2M2B specifically. Mechanism inferred from class.

### Structural gaps
5. **SMILES not in seed data** — Now verified as CCC(C)(C)O from structural analysis. PubChem CID 6405 confirms formula and InChIKey.

6. **Duration discrepancy** — Seed data states total 8–14 hours. Clinical case reports describe intoxication lasting 12–24 hours or longer at higher doses. Both appear valid depending on dose level. Generation agent should note dose-dependency.

7. **ScienceDirect 2022 e-psychonauts case study** — Full article could not be retrieved (403 access denied). Core details obtained through web search summary only (26-year-old male, intoxication + addiction, withdrawal treatment). Citation should be noted as web-retrieved.

8. **No controlled human pharmacokinetic study for oral 2M2B** — All PK data extrapolated from TAME inhalation/ingestion studies where TAA is a metabolite, not the primary administered compound.

9. **No published binding selectivity profile** — Whether 2M2B affects other targets (glycine receptors, voltage-gated sodium channels, nicotinic acetylcholine receptors) as ethanol does at higher concentrations is unknown for this specific compound.

10. **Australia and Canada legal status** — Could not be confirmed. Australia analogue act applicability for 2M2B is disputed on community forums and not resolved by regulatory documentation.

11. **Abuse prevalence data** — Documentation of abuse is largely confined to Eastern Europe (Poland primarily), internet forums, and a small number of case reports. Population-level prevalence data do not exist.